In sur­vival mode, Ex­i­cure cuts to the bone — paus­ing all R&D and chop­ping head­count by 66%

The dras­tic re­struc­tur­ing that Ex­i­cure un­der­took at the end of last year couldn’t save the biotech af­ter all.

In fact, Ex­i­cure — whose take on gene ex­pres­sion once drew the back­ing of Bill Gates and a slate of tech in­vestors — is go­ing for an­oth­er round of lay­offs, this time cut­ting to the bone with 66% of the re­main­ing staffers be­ing let go, while halt­ing all R&D ac­tiv­i­ties and look­ing to di­vest its en­tire pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER